KAMADA LTD. Inactive Instrument
Kamada Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010941198
Pharmaceuticals
| Sales 2024 * | 592M 157M 13.1B | Sales 2025 * | 665M 177M 14.72B | Capitalization | 1.08B 288M 24B |
|---|---|---|---|---|---|
| Net income 2024 * | 53M 14.07M 1.17B | Net income 2025 * | 63M 16.73M 1.39B | EV / Sales 2024 * | 1.83 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.63 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 09/13/09 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 31/17/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 24/19/24 |
Leon Recanati
BRD | Director/Board Member | 76 | 01/05/01 |
David Tsur
FOU | Founder | 73 | 13/90/13 |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.99% | 95.18B | |
| -4.34% | 37.55B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B | |
| +6.22% | 9.09B |
